## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono
✦ LIBER ✦
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience
✍ Scribed by Luca Laurenti; Michela Tarnani; Ilaria Nichele; Stefania Ciolli; Agostino Cortelezzi; Francesco Forconi; Davide Rossi; Francesca Romana Mauro; Giovanni D'Arena; Giovanni Del Poeta; Marco Montanaro; Fortunato Morabito; Caterina Musolino; Vincenzo Callea; Lorenzo Falchi; Alessandra Tedeschi; Achille Ambrosetti; Gianluca Gaidano; Giuseppe Leone; Robin Foà
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 95 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Routine clinical use of alemtuzumab in p
✍
Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig
📂
Article
📅
2006
🏛
John Wiley and Sons
🌐
English
⚖ 250 KB
👁 1 views
Early experience with p-(N,N-di-2-chloro
✍
S. J. Altman; A. Haut; G. E. Cartwright; M. M. Wintrobe
📂
Article
📅
1956
🏛
John Wiley and Sons
🌐
English
⚖ 470 KB
👁 2 views